患者与疾病特征与免疫检查点抑制剂治疗期间严重不良事件之间的关联:一项观察性研究
研究基于MULTOMAB试验前瞻性纳入的641例接受抗PD-1(±抗CTLA-4)治疗的患者,回顾性登记CTCAE v5.0标准下≥3级免疫相关不良事件(irAEs)。106例(17%)发生≥3级irAEs,单药组(n=550)和联合组(n=91)中分析的 patient 与疾病特征均与≥3级irAEs发生无关,亚组分析亦无关联。作者结论认为患者与疾病特征无法预测ICIs治疗中严重不良事件的发生。
要点
- 641例接受抗PD-1(±抗CTLA-4)治疗的患者中,106例(17%)发生≥3级irAEs。
- 单药组(n=550)和联合组(n=91)中,分析的患者与疾病特征均与≥3级irAEs发生无关。
- 黑色素瘤和非小细胞肺癌亚组分析中亦未发现关联;WHO体能状态0分的NSCLC患者(n=34)均未发生≥3级irAEs。
核心结论
- 本研究表明,患者与疾病特征无法预测接受ICIs治疗的患者发生严重不良事件。
研究设计与样本
- 队列研究,患者来自2015年7月至2020年2月前瞻性纳入MULTOMAB试验、接受抗PD-1(±抗CTLA-4)治疗的癌症患者。
- ≥3级irAEs的发生时间与发生情况按CTCAE v5.0回顾性登记。
- 采用Fine和Gray竞争风险Cox回归模型分析患者与疾病特征和irAE发生的关联,分别在单药治疗(抗PD-1,n=550)和联合治疗(抗PD-1+抗CTLA-4,n=91)患者中进行分析。
- 在患者数量最多的肿瘤类型(黑色素瘤和非小细胞肺癌)中进行亚组分析。
主要发现
- 641例患者中,106例(17%)发生≥3级irAEs。
- 单药治疗组(n=550)或联合治疗组(n=91)中,所分析的因素均与≥3级irAE发生无关,亚组分析中亦无关联。
- 值得注意的是,WHO体能状态为0分的NSCLC患者(n=34)均未发生≥3级irAEs。
- NSCLC最常见的组织学类型为腺癌(n=99/55%)和鳞状细胞癌(n=39/22%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: With increasing use of immune checkpoint inhibitors (ICIs) more patients will develop severe and potentially life-threatening immune-related adverse events (irAEs). So far, predictive models for the occurrence of grade ≥3 irAEs are lacking. Therefore, we analysed associations between patient and disease characteristics, and the occurrence of grade ≥3 irAEs. METHODS: Patients with cancer who were treated with anti-PD-1 (+/-anti-CTLA-4) between July 2015 and February 2020, and who were prospectively included in the MULTOMAB-trial, were eligible for this cohort study. Time to and occurrence of grade ≥3 irAEs according to CTCAE v5.0 were retrospectively registered. The associations between patient and disease characteristics and irAE occurrence were analysed using the competing risk cox-regression model of Fine and Gray. Analyses were performed separately in patients treated with monotherapy (anti-PD-1) and combination therapy (anti-PD-1 + anti-CTLA-4). Subgroup analyses were performed in tumour types with the highest number of patients; melanoma and NSCLC. RESULTS: Out of 641 patients, 106 patients (17%) experienced grade ≥3 irAEs. None of the analysed factors were associated with grade ≥3 irAE occurrence in the monotherapy (n = 550) or the combination therapy (n = 91) groups, nor in the subgroup analyses. Of interest, none of the patients with NSCLC with a WHO performance status of 0 (n = 34) experienced grade ≥3 irAEs. Most common NSCLC histology types were adenocarcinoma (n = 99/55%) and squamous cell carcinoma (n = 39/22%). CONCLUDING STATEMENT: This study shows that patient and disease characteristics are not able to predict the occurrence of serious AEs in patients treated with ICIs.
引用
- Basak EA, Vermeer NS, de Joode K, et al. Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study. Eur J Cancer. 2022. PMID: 35988409. doi:10.1016/j.ejca.2022.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。